# Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

> **NCT04181788** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 155 (actual)

## Conditions studied

- Advanced Malignancies
- Non-small-cell Lung Cancer

## Interventions

- **DRUG:** PF-06801591

## Key facts

- **NCT ID:** NCT04181788
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-18
- **Primary completion:** 2022-03-03
- **Final completion:** 2026-06-09
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04181788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04181788, "Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04181788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*